Market capitalization | $94.54m |
Enterprise Value | $77.43m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.07 |
P/S ratio (TTM) P/S ratio | 2.53 |
P/B ratio (TTM) P/B ratio | 20.82 |
Revenue growth (TTM) Revenue growth | 16.14% |
Revenue (TTM) Revenue | $37.34m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Harpoon Therapeutics, Inc. forecast:
2 Analysts have issued a Harpoon Therapeutics, Inc. forecast:
Sep '23 |
+/-
%
|
||
Revenue | 37 37 |
16%
16%
|
|
Gross Profit | 35 35 |
18%
18%
|
|
EBITDA | -35 -35 |
49%
49%
|
EBIT (Operating Income) EBIT | -37 -37 |
47%
47%
|
Net Profit | -31 -31 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Dalton Smart |
Founded | 2015 |
Website | www.harpoontx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.